Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Blood (2024) 144 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2024-199675

Published: 2024

Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Blood (2024) 144 (Supplement 1): 462.

https://doi.org/10.1182/blood-2024-199263

Published: 2024

Journal Articles

Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331

Cindy L Schwartz, Qinglin Pei, Frank G. Keller, Steve Y Cho, David C. Hodgson, Kathleen M McCarten, Yue Wu, Kara M. Kelly, Sharon M. Castellino

Blood (2022) 140 (Supplement 1): 6565–6566.

https://doi.org/10.1182/blood-2022-167188

Published: 2022

Journal Articles

Peripheral Neuropathy in Children with High Risk Hodgkin Lymphoma (HL): The Role of Protocol-Stipulated Dose Modification in the Children's Oncology Group (COG) AHOD1331 Study

Susan K. Parsons, Frank G. Keller, Qinglin Pei, Angie Mae Rodday, Jennifer Belsky, Yue Wu, Angela Punnett, Tara O Henderson, Kara M. Kelly, Sharon M. Castellino

Blood (2022) 140 (Supplement 1): 6550–6551.

https://doi.org/10.1182/blood-2022-167046

Published: 2022

Journal Articles

Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis

Akash Parekh, Frank G. Keller, Kathleen M. McCarten, Sandy Kessel, Steve Cho, Qinglin Pei, Yue Wu, Sharon M. Castellino, Louis S. Constine, Cindy L. Schwartz, David Hodgson, Kara M. Kelly, Bradford S. Hoppe

Blood (2022) 140 (10): 1086–1093.

https://doi.org/10.1182/blood.2022016098

Published: 2022

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis

Christopher J. Forlenza, MD, Nitya Gulati, MBBS, Audrey Mauguen, PhD, Michael J. Absalon, Sharon M. Castellino, MD MSc, Anna Franklin, MD, Frank G. Keller, MD, Neal Shukla, MD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-139480

Published: 2020

Journal Articles

Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children's Oncology Group Trial-AHOD1331

Hema Dave, Mimi Mai, Anushree Datar, Gaye Jenkins, BS, Qinglin Pei, PhD, Yue Wu, MS, Frank G. Keller, MD, Sharon M. Castellino, MD MSc, Terzah M Horton, MD PhD, Catherine M. Bollard, MD MBChB

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136376

Published: 2020

Journal Articles

Premedication and Longer Infusion Time Do Not Reduce the Incidence of Hypersensitivity Reactions to Pegaspargase

Catherine Hughes, PharmD, Valeria Bernardo, PharmD, Susanne Youssef, PharmD, James P. Hughes, PhD, Frank G. Keller, MD, Tamara P. Miller, MDMSc, Sharon M. Castellino, MD MSc, Glen Lew, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-143248

Published: 2020

Journal Articles

Survival Varies By Age and Histology in Classical Hodgkin Lymphoma: A Report from the Children's Oncology Group

Justine M. Kahn, MDMSc, Kara M. Kelly, MD, Qinglin Pei, PhD, Yue Wu, MS, Debra L. Friedman, MD, Tara O. Henderson, MD MPH, David C. Hodgson, MD MPH, FRCPC, Joel A. Kaplan, DO, MPH, Frank G. Keller, MD, Smita Bhatia, MDMPH, Cindy L. Schwartz, MD, Sharon M. Castellino, MD MSc

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-138796

Published: 2020

Journal Articles

Productivity Loss Among Parent Caregivers Is Associated with Poor Health-Related Quality of Life (HRQL) at the Intial Diagnosis of Pediatric Advanced Stage Hodgkin Lymphoma (HL)

Susan K Parsons, MD MRP, Sharon M. Castellino, MD MSc, Angie Mae Rodday, PhD, Frank G Keller, MD, Kara M. Kelly, MD, Rena M Conti, PhD, Debra Lerner, PhD MSc, Tara O. Henderson, MDMPH

Blood (2018) 132 (Supplement 1): 975.

https://doi.org/10.1182/blood-2018-99-117316

Published: 2018

Journal Articles

Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL)

Susan K Parsons, MD MRP, Angie Mae Rodday, PhD MS, Rizvan Bush, MS, Qinglin Pei, PhD, Anem Waheed, MD MPH, Frank G Keller, MD, Kara M. Kelly, MD, Tara O. Henderson, MD MPH, Sharon M. Castellino, MD MSc

Blood (2018) 132 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2018-99-112664

Published: 2018

Journal Articles

Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival

Sunil S. Raikar, Sunita I. Park, Traci Leong, David L. Jaye, Frank G. Keller, John T. Horan, William G. Woods

Blood (2018) 131 (5): 573–577.

https://doi.org/10.1182/blood-2017-09-807602

Published: 2018

Includes: Supplemental data

Journal Articles

Absence of Silent Inactivation Using Intravenous Pegaspargase in Pediatric Acute Lymphoblastic Leukemia

Sarayu Kumar, BA, BSPH, Curtis D Travers, MPH, John Bergsagel, MD, Frank G Keller, MD, Melinda Pauly, MD, Himalee Sabnis, MDMS, Sharon M. Castellino, MD MSc, Glen Lew, MD

Blood (2017) 130 (Supplement 1): 100.

https://doi.org/10.1182/blood.V130.Suppl_1.100.100

Published: 2017

Journal Articles

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Karen E Effinger, MD MS, John Bergsagel, MD, Taylor Lawrence, Frank G Keller, MD, Rebecca Williamson Lewis, MPH, Lillian Meacham, MD, Ann Mertens, PhD, Sharon M. Castellino, MD MSc

Blood (2017) 130 (Supplement 1): 3466.

https://doi.org/10.1182/blood.V130.Suppl_1.3466.3466

Published: 2017

Journal Articles

Incidence and Predictors of Adverse Respiratory Events during Induction Therapy in Children with Acute Myeloid Leukemia

Lane Miller, MD, Sharon M. Castellino, MD MSc, Ann Mertens, PhD, Frank G Keller, MD, William G Woods, MD

Blood (2017) 130 (Supplement 1): 2590.

https://doi.org/10.1182/blood.V130.Suppl_1.2590.2590

Published: 2017

Journal Articles

Isolated Myeloperoxidase Expression in Pediatric B/Myeloid Mixed Phenotype Acute Leukemia Is Associated with Improved Survival Using ALL-Only Regimens

Sunil S Raikar, MD, Sunita Park, MD, Traci Leong, PhD, David L Jaye, MD, Frank G Keller, MD, John T Horan, MD, William G Woods, MD

Blood (2017) 130 (Supplement 1): 1290.

https://doi.org/10.1182/blood.V130.Suppl_1.1290.1290

Published: 2017

Journal Articles

Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Tara O Henderson, MDMPH, Sharon M Castellino, MD, Frank G Keller, MD, Kara M. Kelly, MD, Rachael Curtis, Rena M Conti, PhD, Susan K Parsons, MDMRP

Blood (2016) 128 (22): 3583.

https://doi.org/10.1182/blood.V128.22.3583.3583

Published: 2016

Journal Articles

L-Asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a Large Compassionate Use Protocol.

Paul V. Plourde, MD, Sima Jeha, MD, Nobuko Hijiya, MD, Frank G Keller, MD, Susan R. Rheingold, MD, Zoann E. Dreyer, MD, Gary V. Dahl, MD, Taheri Mercedes, MD, Tim Corn, MD

Blood (2012) 120 (21): 2568.

https://doi.org/10.1182/blood.V120.21.2568.2568

Published: 2012

Journal Articles

The Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma,

Cindy Schwartz, MD, MPH, Lu Chen, PhD, Louis Constine, MD, Suzanne Wolden, Frank G Keller, MD, Kara M Kelly, MD, Debra l Friedman, MD, MS

Blood (2011) 118 (21): 3649.

https://doi.org/10.1182/blood.V118.21.3649.3649

Published: 2011

Journal Articles

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

Frank G Keller, MD, James Nachman, MD, Louis Constine, MD, John Thomson, MD, Kathleen M McCarten, MD, Lu Chen, PhD, Cindy Schwartz, MD

Blood (2010) 116 (21): 767.

https://doi.org/10.1182/blood.V116.21.767.767

Published: 2010

NARROW

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331

Peripheral Neuropathy in Children with High Risk Hodgkin Lymphoma (HL): The Role of Protocol-Stipulated Dose Modification in the Children's Oncology Group (COG) AHOD1331 Study

Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis

Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis

Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children's Oncology Group Trial-AHOD1331

Premedication and Longer Infusion Time Do Not Reduce the Incidence of Hypersensitivity Reactions to Pegaspargase

Survival Varies By Age and Histology in Classical Hodgkin Lymphoma: A Report from the Children's Oncology Group

Productivity Loss Among Parent Caregivers Is Associated with Poor Health-Related Quality of Life (HRQL) at the Intial Diagnosis of Pediatric Advanced Stage Hodgkin Lymphoma (HL)

Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL)

Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival

Absence of Silent Inactivation Using Intravenous Pegaspargase in Pediatric Acute Lymphoblastic Leukemia

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Incidence and Predictors of Adverse Respiratory Events during Induction Therapy in Children with Acute Myeloid Leukemia

Isolated Myeloperoxidase Expression in Pediatric B/Myeloid Mixed Phenotype Acute Leukemia Is Associated with Improved Survival Using ALL-Only Regimens

Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

L-Asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a Large Compassionate Use Protocol.

The Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma,

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only